Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 264 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Depression Clear all
Recruiting Not applicable Interventional

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

NCT04080778
View directory record Official record
Conditions
Bipolar Disorder
Interventions
magnetic seizure therapy (MST), electroconvulsive therapy (ECT)
Device
Lead sponsor
Joao L. DeQuevedo
Other
Eligibility
22 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

BPL-003 Efficacy and Safety in Treatment Resistant Depression

NCT05870540
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
BPL-003
Drug
Lead sponsor
Beckley Psytech Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Rogers, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Active, not recruiting Early Phase 1 Interventional

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

NCT03573349
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional

DBS for Depression

NCT06096207
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Medtronic SenSight Directional DBS lead
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Not applicable Interventional Results available

Maintenance TMS in Treatment Resistant Depression

NCT06682299
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
Transmagnetic Stimulation, Electroconvulsive Therapy
Device
Lead sponsor
Austin Messner
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

NCT02360280
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
ketamine, midazolam
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting No phase listed Observational

Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy

NCT05905705
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Electroencephalography (EEG), Quantitative Measurements of Sleep Microstructure
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated No phase listed Observational

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

NCT01598324
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429
View directory record Official record
Conditions
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions
SCC DBS
Device
Lead sponsor
Paul Holtzheimer
Other
Eligibility
22 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort

NCT03240692
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Accelerated theta-burst stimulation treatment
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Jul 21, 2026, 9:30 PM EDT
Not yet recruiting Phase 4 Interventional

Biomarker-Guided Antidepressant Selection

NCT07680140
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine, fMRI
Interventions
TMS, Ketamine
Device · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Terminated Not applicable Interventional Results available

iTBS in Refractory Pediatric Depression

NCT03845504
View directory record Official record
Conditions
Depression
Interventions
Intermittent Theta Burst Stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jul 21, 2026, 9:30 PM EDT
Not listed Phase 2Phase 3 Interventional

Neural and Antidepressant Effects of Propofol

NCT03684447
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Propofol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 21, 2026, 9:30 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Not yet recruiting No phase listed Observational

Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients

NCT06101914
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 21, 2026, 9:30 PM EDT
Withdrawn Phase 2 Interventional

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

NCT03290963
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jul 21, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Placebo Midazolam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jul 21, 2026, 9:30 PM EDT
Active, not recruiting Not applicable Interventional

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

NCT02046330
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Deep Brain Stimulation Model 3387 Model 3389
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
22 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 21, 2026, 9:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Long-term Observation of Participants With Mood Disorders

NCT04877977
View directory record Official record
Conditions
Depression, Suicide Risk
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 21, 2026, 9:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

NCT04239963
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jul 21, 2026, 9:30 PM EDT